MedPath

Chabiotech Co., Ltd.

🇰🇷South Korea
Ownership
Private, Subsidiary
Employees
-
Market Cap
-
Website
http://www.chabio.com

Clinical Trials

7

Active:1
Completed:5

Trial Phases

1 Phases

Phase 1:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (100.0%)

Phase 1 Clinical Trial of CordSTEM-ST

Phase 1
Completed
Conditions
Premature Ovarian Insufficiency
Interventions
First Posted Date
2024-08-29
Last Posted Date
2025-05-31
Lead Sponsor
CHABiotech CO., Ltd
Target Recruit Count
6
Registration Number
NCT06578039
Locations
🇰🇷

CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

Phase 1
Completed
Conditions
Solid Tumor
First Posted Date
2020-09-21
Last Posted Date
2024-04-08
Lead Sponsor
CHABiotech CO., Ltd
Target Recruit Count
6
Registration Number
NCT04557306
Locations
🇰🇷

CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain

Phase 1
Completed
Conditions
Chronic Low-back Pain
Disc Degeneration
First Posted Date
2020-08-28
Last Posted Date
2023-08-30
Lead Sponsor
CHABiotech CO., Ltd
Target Recruit Count
36
Registration Number
NCT04530071
Locations
🇰🇷

CHA Bundand Medical Center, Seongnam-si, Korea, Republic of

Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

Phase 1
Active, not recruiting
Conditions
Alzheimer's Disease
First Posted Date
2016-09-14
Last Posted Date
2024-04-09
Lead Sponsor
CHABiotech CO., Ltd
Target Recruit Count
24
Registration Number
NCT02899091
Locations
🇰🇷

Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction

Phase 1
Completed
Conditions
Cerebral Infarction
First Posted Date
2015-03-04
Last Posted Date
2024-04-09
Lead Sponsor
CHABiotech CO., Ltd
Target Recruit Count
18
Registration Number
NCT02378974
Locations
🇰🇷

CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.